Elanco Animal Health Incorporated ELAN
Set alert
At close · Oct 30
After hours · Oct 30, 5:05 PM ET
- YTD
- +1.90%
- 1 year
- +2.17%
- Open
- 23.48
- Prev close
- 23.24
- Mkt cap
- 11.52B
- Vol
- 3.45M
- Avg vol
- 6.15M
- EPS
- -0.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 22.93
- High
- 23.48
- Forward P/E
- 18.12
- Beta
- 1.71
- Short ratio
- 5.57
- Inst. own
- 115.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2026
- 50-d avg
- 23.13
- 200-d avg
- 23.80
- 1y target
- 30.23
2Y chart
Events in this range
- Aug 7, 2025Earnings: 0.26; estimate 0.2; surprise 30%
- Nov 5, 2025Earnings: 0.19; estimate 0.13; surprise 46.15%
- Feb 24, 2026Earnings: 0.13; estimate 0.11; surprise 18.18%
- May 6, 2026Earnings: 0.4; estimate 0.3456; surprise 15.74%
- Jul 22, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Aug 5, 2026Earnings: 0.34; estimate 0.2692; surprise 26.3%
- Aug 6, 2026Rating: Keybanc · Overweight → Overweight
- Aug 6, 2026Rating: UBS · Buy → Buy
- Oct 16, 2026Rating: Goldman Sachs · — → Buy
- Oct 20, 2026Downgrade: Jefferies · Buy → Hold
- Oct 29, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
Signals (95)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 29, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 21, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 27, 2026 | 7 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| SMA: Bullish | Mar 24, 2026 | 7 months ago |
| SMA: Bearish | Mar 20, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 19, 2026 | 7 months ago |
| SMA: Bullish | Mar 17, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 13, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 19, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Dec 9, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 3, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 5, 2025 | 12 months ago |
| RSI: Overbought | Nov 3, 2025 | 12 months ago |
| MACD: Buy Signal | Oct 20, 2025 | 1 year ago |
| RSI: Overbought | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| RSI: Overbought | Oct 1, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 30, 2025 | 1 year ago |
| RSI: Overbought | Sep 8, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Aug 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 7, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 7, 2025 | 1 year ago |
| RSI: Overbought | Aug 7, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 5, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| RSI: Overbought | Jul 2, 2025 | 1 year ago |
| RSI: Overbought | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 3, 2025 | 1 year ago |
| RSI: Overbought | May 28, 2025 | 1 year ago |
| RSI: Overbought | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 7, 2025 | 1 year ago |
| RSI: Overbought | May 7, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 18, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 4, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| SMA: Bullish | Jan 30, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
Key statistics
- Market cap
- 11.52B
- Enterprise value
- 15.31B
- Trailing P/E
- 0.00
- Forward P/E
- 18.12
- PEG ratio
- 4.04
- Price / sales
- 2.30
- Price / book
- 1.75
- EPS (TTM)
- -0.41
- Beta
- 1.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -3.96%
- Revenue (TTM)
- 5.02B
- Revenue growth
- 10.20%
- Free cash flow
- 826.88M
- Total cash
- 530.00M
- Total debt
- 4.23B
- Return on equity
- -2.98%
- Shares outstanding
- 499.62M
- Short % of float
- 9.89%
- 50-day average
- 23.13
- 200-day average
- 23.80
Analyst view
Consensus: buy
- Target (low)
- 24.00
- Target (mean)
- 30.23
- Target (high)
- 34.00
- Strong buy4
- Buy9
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 6, 2026
Expected Nov 6, 2026. Consensus EPS estimate 0.20328.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2026 | Sep 30, 2026 | 0.2028 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.2692 | 0.34 | +0.07 | +26.30% |
| May 6, 2026 | Mar 31, 2026 | 0.3456 | 0.40 | +0.05 | +15.74% |
| Feb 24, 2026 | Dec 31, 2025 | 0.11 | 0.13 | +0.02 | +18.18% |
| Nov 5, 2025 | Sep 30, 2025 | 0.13 | 0.19 | +0.06 | +46.15% |
| Aug 7, 2025 | Jun 30, 2025 | 0.20 | 0.26 | +0.06 | +30.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 20, 2026 | Jefferies | down | Buy | Hold |
| Oct 16, 2026 | Goldman Sachs | init | — | Buy |
| Aug 6, 2026 | UBS | main | Buy | Buy |
| Aug 6, 2026 | Keybanc | main | Overweight | Overweight |
| Jul 22, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- elanco.com
News
- Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Morgan Stanley Maintains Equal-Weight on Elanco Animal Health, Lowers Price Target to $25
- This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
- Elanco Animal Health Appoints Jamie Preston as Chief People Officer
- This Chipotle Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
- Occidental Petroleum To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Tuesday
- This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
- Jefferies Downgrades Elanco Animal Health to Hold, Lowers Price Target to $24
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More
- Elanco Animal Health (NYSE:ELAN) Insider Timothy Bettington Sells 4,350 Shares of Company Stock
Your note
Sign in to keep a note on ELAN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BETTINGTON TIMOTHY J | Officer | Sale | Oct 14, 2026 | 138,911 |
| CABRAL RAMIRO MARTIN | Officer | Stock Award(Grant) | Feb 26, 2026 | 290,366 |
| DE BRABANDER ELLEN | Officer | Stock Award(Grant) | Mar 31, 2026 | 280,821 |
| HOOVER R DAVID | Director | Stock Award(Grant) | May 20, 2026 | 277,371 |
| KINARD DAVID S | Officer | Stock Award(Grant) | Feb 26, 2026 | 217,697 |
| KURZIUS LAWRENCE ERIK | Director | Purchase | Aug 19, 2026 | 188,647 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Inc. | 13.49% | 67,397,025 | 1.55B | Jun 29, 2026 |
| FMR, LLC | 11.40% | 56,948,819 | 1.31B | Jun 29, 2026 |
| Blackrock Inc. | 9.78% | 48,849,973 | 1.13B | Jun 29, 2026 |
| Primecap Management Company | 9.10% | 45,445,012 | 1.05B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.75% | 28,750,719 | 662.99M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 5.09% | 25,417,271 | 586.12M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 8.63% | 43,107,500 | 994.06M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 17,796,673 | 410.39M | Sep 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 3.55% | 17,751,139 | 409.34M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 15,872,148 | 366.01M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 11,448,318 | 264.00M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.07% | 10,339,390 | 238.43M | Aug 30, 2026 |